total population) of 8.6% in 2017, 8 and Pakistan with an estimated HCV Ab prevalence of 4.9% in 2007-2008. 9 While the HCV epidemic in Egypt is well-characterized and the drivers of HCV transmission have been elucidated and/or quantified, 8, [10] [11] [12] [13] [14] [15] [16] Pakistan's epidemic remains overall poorly understood and characterized. 17 The main initial expansion of the HCV epidemic in Pakistan could have been linked to the first five-year health plan implemented in the country in the 1950s. 18 With the 6th largest population globally, 19, 20 it is believed that Pakistan may host the second largest number of HCV infections after China. 21 Past and potential future trends of the HCV epidemic in Pakistan need to be established. Unlike other countries with large epidemics where multiple nationally representative and population-based prevalence surveys have been conducted, [22] [23] [24] only one such survey was conducted in Pakistan and nearly a decade ago. 9 While HCV epidemics appear to be contracting across countries globally, 8, 21, 24 it has been suggested that Pakistan's epidemic may be bucking this trend with a growing epidemic. [25] [26] [27] Different lines of evidence further suggest a high ongoing HCV incidence, driven possibly by various healthcare-related procedures, such as reuse of injections, inadequate blood screening and deficient infection control, among others. [28] [29] [30] [31] With the poor characterization of one of the world's largest HCV epidemics, we aimed to quantitatively characterize the level and trend of the HCV epidemic in Pakistan since 1980. We further aimed to forecast its potential evolution up to 2050. Specifically, we assessed the temporal evolution and age distribution of HCV Ab prevalence, chronic infection prevalence, number of infected individuals, annual number of new HCV infections and incidence rate, thereby providing a comprehensive characterization of this epidemic, past, present and future.
Our overarching goal in this study was to inform HCV response in Pakistan by providing the evidence base necessary to outline HCV policy guidelines, design and implement HCV prevention and treatment programmes and set resource allocation and strategic priorities.
A major strength of the present quantitative assessment is that it is grounded on an extensive base of epidemiologic evidence for HCV Ab prevalence. Our study utilized all HCV Ab prevalence measures systematically identified in Pakistan through a recent systematic review of HCV epidemiology in this country. 30 
| MATERIALS AND METHODS

| Mathematical model
A deterministic dynamical mathematical model, based on extension and adaptation of earlier models, 8, 32 was constructed to describe HCV transmission in Pakistan. A schematic diagram of the model can be seen in Figure S1 of Supplementary Material (SM). The model consisted of a set of coupled nonlinear differential equations that stratified the population into compartments according to age group, HCV status and stage of infection, and level of HCV risk of exposure. Natural history of HCV infection was divided into the three stages of primary acute infection, secondary acute infection and chronic infection.
8,33
Secondary acute infection is defined as HCV acute infection upon reinfection-that is acute infection in persons who acquired HCV infection in the past but spontaneously cleared the prior infection. The duration that an individual spends in a specific risk stratum was set through a hierarchy starting from 12 years for the highest risk group, up to 40 years for the lowest risk group. Individuals who leave their risk group were distributed proportionally across all risk groups.
The distribution of the population across the risk groups followed a gamma distribution, while the distribution of exposure risk across risk groups followed a power-law function. This parametrization is informed by earlier mathematical modelling work. 8, 34, 35 The mixing between the different risk groups and age groups was described by mixing matrices that incorporated both an assortative component (where individuals are chosen preferentially from within the same risk or age group) and a proportionate component (where individuals are chosen with no preferential bias based on risk or age group). 36, 37 The force of infection was expressed in terms of the effective rate of contacts conducive for transmission, HCV transmission probability per contact by HCV stage, mixing among the different risk groups and mixing among the different age groups.
We did not incorporate scale-up of HCV treatment in the model as the purpose of the model was to assess the evolution of the HCV epidemic per current status and to provide the baseline for assessment of the impact of intervention programmes in future. Scale-up of HCV treatment in Pakistan has been very limited up to today. 38 Further details on the model can be found in Section 1 of SM.
| Epidemiologic measures
We used several epidemiologic measures to characterize the HCV epidemic in Pakistan. These measures were chosen because of their epidemiological relevance and their importance in informing the public health response. A listing of these measures and their definitions can be found in Table 1 .
| Data sources and model fitting
The model was parameterized using current data for HCV transmission and natural history. The model's parameter values, along with their justifications and references, are listed in Table S1 in SM. The total population size of Pakistan in 2017 was obtained from the 6th
Population and Housing Census-2017. 20 Other demographics such as population size by age group and its past and future projections were obtained from the database of the Population Division of the United Nations Department of Economic and Social Affair. 19 The level of HCV Ab prevalence by age group was fitted to the nationally representative and population-based HCV Ab prevalence survey conducted in 2007-2008. 9 To generate a time series of HCV Ab prevalence data, we used 342 HCV Ab prevalence measures that were identified through a systematic review of HCV epidemiology in Pakistan. 30 The systematic review was informed by the Cochrane Collaboration handbook 39 and reported its findings using the PRISMA guidelines. Pakistan's past and future demographics. The model fitting to the national survey data was given 100% weight, while the model fitting to the anchored HCV Ab prevalence measures was given 10% weight.
The model was fitted to HCV Ab prevalence trend data using a nonlinear, least-square fitting method. This technique was implemented in MATLAB ®41 using the Nelder-Mead simplex algorithm. 42 To account for potential growth or decline in HCV Ab prevalence over the last few decades, we parameterized the temporal variation in the overall effective rate of infectious contacts through a generalized Gaussian function. This function provided the best fit to HCV Ab prevalence trend data.
Further details on data sources and model fitting can be found in Section 2 of SM.
| Uncertainty analysis
We conducted a multivariable uncertainty analysis to assess the range of uncertainty around our epidemic projections. We specifically implemented 1 000 runs of the model applying Latin hypercube sampling from a multidimensional distribution of the structural parameters of the model-assuming a 25% uncertainty around the point estimates of these parameters. The structural parameters included the duration that an individual spends in a specific risk group, the degree of assortativeness, the scale parameter in the gamma distribution of the population across risk groups and the exponent parameter in the power-law function of the distribution of risk of exposure. The mean of the projected epidemic trajectories and associated 95% UI was reported for HCV Ab prevalence, HCV incidence and HCV incidence rate. Figure S2 shows the model's fit to Pakistan's demographics, and Figure 1B displays the trend in HCV Ab prevalence in the different age groups. The HCV Ab prevalence by age group followed a similar pattern to that in the whole population, but the peak in HCV Ab prevalence shifted to later years for the older age groups. The earliest peak in Ab prevalence was in 1991 for those aged 0-4 years, and the latest peak in HCV Ab prevalence was in 2014 for those aged >60 years.
| RESULTS
Measure Definition
HCV Ab prevalence Proportion of a given population that are positive for HCV Ab, that is, proportion of the population that have ever been infected with HCV.
Prevalence of HCV chronic infection
Proportion of a given population that are HCV Ab positive and RNA positive, that is, proportion of the population that are chronically infected with HCV.
Annual number of new HCV infections (also known as HCV incidence)
Number of new HCV infections in a given population over a duration of a year.
HCV incidence rate (also known as force of infection)
Number of new HCV infections per person-time of the at-risk population, that is, HCV incidence divided by the population size of the at-risk susceptible population.
T The annual number of new HCV infections (that is HCV incidence) and its 95% UI are shown in Figure 3A and Figure S5B , respectively. was projected to decline to 98 120.
HCV incidence rate in the total population and its 95% UI can be seen in Figure 3B and Figure S5C , respectively. The incidence rate peaked in 1988 at 343 infections per 100 000 person-year and declined steadily thereafter. In 2017, it was estimated at 99 per 100 000 person-year. By 2030, it was projected to decline to 62 per 100 000 person-year, and by 2050, it was projected to decline to 36 per 100 000 person-year. 
| DISCUSSION
We characterized the HCV epidemic in Pakistan, one of the largest epidemics worldwide, using an analytical approach based on mathematical modelling. Our results show that both HCV prevalence and incidence have been declining for about two decades, but very slowly. In the context of HCV epidemics globally, 8, 21, 24 it is remarkable that this large-scale epidemic is a "recent" and "young" epidemic that was expanding for several decades up to the 1990s and that the majority of incidence has been occurring among those 20-39 years of age.
The epidemic also exhibited a strong age cohort effect (Figures 4 and 5). As incidence continues its decline over the coming decades and the young infected cohort ages, infection burden will shift to older ages and will be highest among those >60 years of age by 2050. Given also the decades-long lag between infection and disease sequelae, 33 it is likely that HCV disease burden of fibrosis, cirrhosis and liver cancer will continue to rise, for several decades, if the epidemic is not controlled.
The observed declines in HCV Ab prevalence, chronic infection prevalence, incidence and incidence rate (Figures 1, 2 and 3 ) could be attributed to several factors, none of which is certain or conclusive.
The first is a cohort effect where older age groups at higher HCV prevalence, possibly because of specific historical events such as Pakistan's first five-year health plan in the 1950s, 18 are dying and being replaced by younger cohorts who have a lower risk of HCV exposure and lower HCV prevalence. A related potential effect is "demographic dilution" of prevalence and incidence rate, with the relatively high fertility rate in Pakistan. 19, 20 Every year, a large number of newborns enter the country's population who have not been exposed to HCV. This dilutes HCV prevalence and incidence rate as the denominator for calculating these measures is increasing at a higher rate with time than the numerator of HCV infections.
Another possible factor contributing to these declines is the increasing coverage of blood screening and possibly improved infection control in at least a segment of the healthcare system. [43] [44] [45] Experience from other countries suggests that even limited rollout of interventions can result in a rapid decline in HCV incidence rate, such as the large decline observed in the United States immediately following the discovery of the virus. 46 A related factor could be increasing awareness about the virus and its transmission patterns within the healthcare system or in the general public, 47, 48 which may have led (indirectly) to reduced exposures. It bears notice that globally, HCV prevalence and incidence rate appear to be declining, even in countries in which (or when) there have been limited HCV response. 8, 21, 24 For example, in Egypt, there have been extensive declines in incidence and incidence rate even well before expansion of prevention and treatment programmes. 8 With such slowly declining epidemic, our results demonstrate the gravity of the HCV epidemic in Pakistan. We estimated that there are currently over 8 million HCV Ab-positive individuals, and over 6 million chronically infected individuals that are in need of treatment-nearly 10% of the global number of chronic infections. 7 Although HCV incidence has declined by nearly 50% since its peak in the early 1990s, close to 200 000 new HCV infections were estimated to have occurred in 2017-apparently over 10% of the global HCV incidence and the highest incidence for any country worldwide. 7, 38 Despite the forecasted decline in HCV chronic infection prevalence over the coming decades in Pakistan, prevalence will remain at high levels, far higher than the global target of HCV elimination by 2030. 5, 6 All of these findings highlight the alarming nature of this epidemic and the urgent need for scale-up of both treatment and prevention efforts to avoid a massive disease burden that Pakistan may not afford to confront. The striking recent and young nature of the HCV epidemic in
Pakistan is best seen in context of the HCV epidemic in Egypt, one of the largest epidemics worldwide. procedures. There is a critical need to understand the drivers of this persistently high HCV incidence in this country. On the bright side, the predicted declining incidence since the 1990s (Figure 3) , right after the discovery of HCV, 55, 56 suggests that the improvements in blood screening and injection safety may have already had an impact in reducing ongoing transmission in Pakistan. 57 Our findings highlight the urgency of scaling-up treatment and prevention programmes in Pakistan. Pakistan has been recently offered heavily discounted prices for DAA-branded drugs 58 and has also introduced generics at a cost of less than $200 for a full treatment course. 58 Despite the increasing availability of affordable DAAs, scale-up of treatment has been very limited. 38 It is estimated that only 311 035 chronic infections have been treated since introduction of DAAs in 2013. 38 With the large-scale epidemic and ongoing incidence, The conducted uncertainty analysis indicated that Pakistan's HCV epidemic has been slowly declining ( Figure S5 ). However, the 95% UIs of the projected epidemic encompassed a broad range of trajectories, with some suggesting stable or even slightly increasing epidemic ( Figure S5 ). These results highlight the need for further
updates of the present model as new data become available and indicate the need for further analyses of existing data, such as linear and nonlinear meta-regressions of the systematically collected HCV prevalence data. 30 Future projections were generated by fitting the model to past and present data, but future evolution of the epidemic can be influenced by factors that are difficult to predict, such as the scale-up of DAA treatment or rollout of prevention interventions. We assumed no scale-up of treatment so far in Pakistan, but this is justified given the limited treatment coverage up to today. 38 Most HCV natural history and transmission parameters found in the literature and used in the model were from studies conducted on PWID, and it is uncertain whether these studies are generalizable to the wider population. We did not incorporate disease-related mortality, but the relative risk of mortality with HCV infection is too small to affect significantly our projections. 8 We did not explicitly factor mother to child transmission in the model, but the contribution of this mode of exposure is limited relative to the overall infection burden in Pakistan. 31 In conclusion, Pakistan is enduring an HCV epidemic of historical proportions. Although the epidemic appears to be contracting, the rate of decline is slow and chronic infection prevalence will persist at levels much higher than the global target of elimination by 2030. Over 
